Laboratory Parameters in 24 Patients With Types 2A, 2B, 2N, Type 3, and Acquired vWD
| Patients . | vWFAg IU/dL . | vWFRCo IU/dL . | BT (min) . | CT (sec) . | |
|---|---|---|---|---|---|
| ADP . | Epi . | ||||
| Type 2A | |||||
| 1 | 75 | 43 | 8.5 | >250 | >250 |
| 2 | 92 | 24 | 8.5 | >250 | >250 |
| 3 | 85 | 23 | 18 | >250 | >250 |
| 4 | 79 | 22 | >20 | >250 | >250 |
| 5 | 69 | 22 | >20 | >250 | >250 |
| 6 | 30 | 14 | >20 | >250 | >250 |
| 7 | 72 | 14 | >20 | >250 | >250 |
| 8 | 45 | <3 | >20 | >250 | >250 |
| 9 | 92 | <3 | >20 | >250 | >250 |
| 10 | 50 | <3 | >20 | >250 | >250 |
| Type 2B | |||||
| 1* | 208 | 88 | 9 | 3-151 | 184 |
| 2 | 51 | 17 | >20 | >250 | >250 |
| 3 | 61 | 15 | 14 | >250 | >250 |
| Type 2N | |||||
| 1 | 83 | 78 | 5.5 | 81 | 135 |
| 2 | 67 | 54 | 4 | 94 | 141 |
| Type 3 | |||||
| 1 | <1 | <3 | >20 | >250 | >250 |
| 2 | <1 | <3 | >20 | >250 | >250 |
| 3 | <1 | <3 | >20 | >250 | >250 |
| 4 | <1 | <3 | >20 | >250 | >250 |
| Acquired form | |||||
| 1 | 49 | 40 | 12 | 140 | 166 |
| 2 | 42 | 36 | 7.5 | 179 | >250 |
| 3 | 48 | 33 | 9 | >250 | >250 |
| 4 | 27 | 21 | 18 | >250 | >250 |
| 5 | 14 | 3 | 10 | >250 | >250 |
| Patients . | vWFAg IU/dL . | vWFRCo IU/dL . | BT (min) . | CT (sec) . | |
|---|---|---|---|---|---|
| ADP . | Epi . | ||||
| Type 2A | |||||
| 1 | 75 | 43 | 8.5 | >250 | >250 |
| 2 | 92 | 24 | 8.5 | >250 | >250 |
| 3 | 85 | 23 | 18 | >250 | >250 |
| 4 | 79 | 22 | >20 | >250 | >250 |
| 5 | 69 | 22 | >20 | >250 | >250 |
| 6 | 30 | 14 | >20 | >250 | >250 |
| 7 | 72 | 14 | >20 | >250 | >250 |
| 8 | 45 | <3 | >20 | >250 | >250 |
| 9 | 92 | <3 | >20 | >250 | >250 |
| 10 | 50 | <3 | >20 | >250 | >250 |
| Type 2B | |||||
| 1* | 208 | 88 | 9 | 3-151 | 184 |
| 2 | 51 | 17 | >20 | >250 | >250 |
| 3 | 61 | 15 | 14 | >250 | >250 |
| Type 2N | |||||
| 1 | 83 | 78 | 5.5 | 81 | 135 |
| 2 | 67 | 54 | 4 | 94 | 141 |
| Type 3 | |||||
| 1 | <1 | <3 | >20 | >250 | >250 |
| 2 | <1 | <3 | >20 | >250 | >250 |
| 3 | <1 | <3 | >20 | >250 | >250 |
| 4 | <1 | <3 | >20 | >250 | >250 |
| Acquired form | |||||
| 1 | 49 | 40 | 12 | 140 | 166 |
| 2 | 42 | 36 | 7.5 | 179 | >250 |
| 3 | 48 | 33 | 9 | >250 | >250 |
| 4 | 27 | 21 | 18 | >250 | >250 |
| 5 | 14 | 3 | 10 | >250 | >250 |
*During pregnancy (5 months).
Obstruction of the capillary by platelet aggregates.